Vericel Corp history

Prior to beginning his legal career, Sean served as an Air Defense Artillery Officer in the United States Army, having graduated from the United States Military Academy at West Point in 1995.

In 1997, he joined the UK’s Senior Civil Service as a senior medical officer at the UK’s Department of Health, regulating medical device manufacturers and advising senior government officials and Ministers of State.

Alan Rubino has been a member of the Vericel Board of Directors since 2005.

Heidi joined Vericel in September of 2010 and is responsible for leading the overall administration and strategic direction of Vericel’s Human Resources function.

Director since August 2013

Roland has over 20 years of experience with Vericel’s brands, having joined the company in 2014 by virtue of the acquisition of Sanofi-Genzyme’s cell therapy and regenerative medicine business unit.

Doctor Steven Gilman has been a member of the Vericel Board of Directors since 2015.

Prior to that, Doctor Wotton served as the President, Chief Executive Officer and a member of the board of directors of Ocata Therapeutics, Inc. until its acquisition by Astellas Pharma US, Inc. in February 2016.

Mike joined Vericel in April of 2017 with over 28 years of regulatory, quality assurance, and clinical research experience with a variety of medical device, combination product, small molecule, biologic, and advanced therapy technologies.

Jon joined Vericel in August 2018 and leads the Clinical Development, Pharmacovigilance and Medical Affairs functions.

Doctor Paul Wotton is Chief Executive Officer and a member of the board of directors of Obsidian Therapeutics, Inc. – a position he has held since April 2019.